Optimizing the dose and duration of therapy for chronic hepatitis C. - Wikidata - awgldk - TriplyDB

Optimizing the dose and duration of therapy for chronic hepatitis C.

Optimizing the dose and duration of therapy for chronic hepatitis C.

http://www.wikidata.org/entity/Q33855483

about

Optimal Duration of Pegylated Interferon Plus Ribavirin Therapy for Chronic Hepatitis C Genotype 3 Patients who do not Achieve Rapid Virological Response.Efficacy of peg-interferon-α-2a plus ribavirin for patients aged 60 years and older with chronic hepatitis C in Korea.

P2860

Q40108841-F9FEF5A3-29EF-463B-B891-197B5BB62D60 Q43034449-1A9C33C1-CD4F-4173-9E1B-ED2236E81C21

P2860

Optimizing the dose and duration of therapy for chronic hepatitis C.

http://www.wikidata.org/entity/Q33855483

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Optimizing the dose and duration of therapy for chronic hepatitis C.

@ast

Optimizing the dose and duration of therapy for chronic hepatitis C.

@en

type

label

Optimizing the dose and duration of therapy for chronic hepatitis C.

@ast

Optimizing the dose and duration of therapy for chronic hepatitis C.

@en

prefLabel

Optimizing the dose and duration of therapy for chronic hepatitis C.

@ast

Optimizing the dose and duration of therapy for chronic hepatitis C.

@en

P1433

Q33855483-CEEAE1BE-DFC4-4EDB-968E-C0A30302DF8C

P1476

Q33855483-374ED96C-96BA-4C03-9361-3EB839733E43

P2093

Q33855483-74E75CCA-6A08-4148-9CD5-78A052379F6B

Q33855483-961BEFC5-CAA5-41F7-B566-10682F1B54F7

Q33855483-9E0B5116-3026-4539-8395-CA469097C811

Q33855483-B1014E80-2034-4882-B923-6FE0CAD996AF

P2860

Q33855483-0E6D8340-FD04-4C70-9EE7-446B40EF9DE9

Q33855483-183B7862-7F2F-433B-B243-EE9336B67765

Q33855483-18DA0A86-E77D-401C-9A84-DC2BE13C6DCD

Q33855483-1C2F9242-45C4-4EC2-917E-7C954A1BB934

Q33855483-1DFD5579-B746-455D-8632-EF00767CA2D2

Q33855483-286E34B3-7A1E-4EFB-B916-F0BC8A8489E2

Q33855483-2B663984-1CD2-4EB6-8F11-1FCACCFD0B34

Q33855483-314C9972-5F68-4600-8EAC-159C95AD4206

Q33855483-333FB08C-A1B7-46BA-A030-C6C8BD4CCD91

Q33855483-33E333B5-B04B-4142-B602-089D7C8A170C

P304

Q33855483-8046C5EE-B3CB-4EC4-8AE4-37138F716E7D

P31

Q33855483-FB826725-B3E2-478F-9169-B9E72152441C

P356

Q33855483-BFB44818-E85D-4EF1-9F7F-1251A9313424

P433

Q33855483-64C51A80-1731-43F0-AFAC-6A19551B44AA

P478

Q33855483-B4BA7494-0639-46AA-9224-D014E5B1933E

P577

Q33855483-53B9FCF8-9D09-4352-8837-FBEF80F4ACE4

P5875

Q33855483-0E47AFCC-9507-4C48-93EB-855442055344

P698

Q33855483-D04BCDD8-96CE-4E26-9466-BE94E8A8ED5C

P932

Q33855483-E1104E7C-5DDA-479F-904F-AEC23487F799

P356

P1433

P1476

Optimizing the dose and duration of therapy for chronic hepatitis C.

@en

P2093

Erik Groessl

http://www.w3.org/2001/XMLSchema#string

Helen Yee

http://www.w3.org/2001/XMLSchema#string

Nipaporn Pichetshote

http://www.w3.org/2001/XMLSchema#string

Samuel B Ho

http://www.w3.org/2001/XMLSchema#string

P2860

Extended-therapy duration for chronic hepatitis C, genotype 1: The long and the short of it

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

The impact of diagnosis of hepatitis C virus on quality of life.

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection.

Chronic hepatitis C: an age wave of disease burden.

American Gastroenterological Association technical review on the management of hepatitis C.

P304

1-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5009/GNL.2009.3.1.1

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44608862

http://www.w3.org/2001/XMLSchema#string

P698

20479894

http://www.w3.org/2001/XMLSchema#string

P932

2871559

http://www.w3.org/2001/XMLSchema#string